54 45

Cited 0 times in

Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity

 Ji-Hoon Park  ;  Min-Hee Kim  ;  Edwin Sutanto  ;  Seok-Won Na  ;  Min-Jae Kim  ;  Joon Sup Yeom  ;  Myat Htut Nyunt  ;  Mohammed Mohieldien Abbas Elfaki  ;  Muzamil Mahdi Abdel Hamid  ;  Seok Ho Cha  ;  Sisay Getachew Alemu  ;  Kanlaya Sriprawat  ;  Nicholas M Anstey  ;  Matthew J Grigg  ;  Bridget E Barber  ;  Timothy William  ;  Qi Gao  ;  Yaobao Liu  ;  Richard D Pearson  ;  Ric N Price  ;  Francois Nosten  ;  Sung-Il Yoon  ;  Joo Hwan No  ;  Eun-Taek Han  ;  Sarah Auburn  ;  Bruce Russell  ;  Jin-Hee Han 
 PLOS NEGLECTED TROPICAL DISEASES, Vol.16(6) : e0010492, 2022-06 
Journal Title
Issue Date
Animals ; Antigens, Protozoan ; Genetic Variation ; Humans ; Malaria, Vivax* ; Merozoites ; Plasmodium vivax* ; Polymorphism, Genetic ; Protozoan Proteins / metabolism ; Reti
Plasmodium vivax is the most widespread cause of human malaria. Recent reports of drug resistant vivax malaria and the challenge of eradicating the dormant liver forms increase the importance of vaccine development against this relapsing disease. P. vivax reticulocyte binding protein 1a (PvRBP1a) is a potential vaccine candidate, which is involved in red cell tropism, a crucial step in the merozoite invasion of host reticulocytes. As part of the initial evaluation of the PvRBP1a vaccine candidate, we investigated its genetic diversity and antigenicity using geographically diverse clinical isolates. We analysed pvrbp1a genetic polymorphisms using 202 vivax clinical isolates from six countries. Pvrbp1a was separated into six regions based on specific domain features, sequence conserved/polymorphic regions, and the reticulocyte binding like (RBL) domains. In the fragmented gene sequence analysis, PvRBP1a region II (RII) and RIII (head and tail structure homolog, 152-625 aa.) showed extensive polymorphism caused by random point mutations. The haplotype network of these polymorphic regions was classified into three clusters that converged to independent populations. Antigenicity screening was performed using recombinant proteins PvRBP1a-N (157-560 aa.) and PvRBP1a-C (606-962 aa.), which contained head and tail structure region and sequence conserved region, respectively. Sensitivity against PvRBP1a-N (46.7%) was higher than PvRBP1a-C (17.8%). PvRBP1a-N was reported as a reticulocyte binding domain and this study identified a linear epitope with moderate antigenicity, thus an attractive domain for merozoite invasion-blocking vaccine development. However, our study highlights that a global PvRBP1a-based vaccine design needs to overcome several difficulties due to three distinct genotypes and low antigenicity levels.
Files in This Item:
T9992022833.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Yeom, Joon Sup(염준섭) ORCID logo https://orcid.org/0000-0001-8940-7170
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.